Treace Medical Concepts, Inc. shares rise 3.35% after-hours after Q2 revenue beats estimates.

Treace Medical Concepts, Inc. rose 3.35% in after-hours trading, driven by the company's Q2 2025 revenue growth of 7%, which exceeded analyst expectations. The company also reported an 18% improvement in net loss and a 58% reduction in adjusted EBITDA loss. Additionally, Treace Medical expanded its bunion technology portfolio with new systems and increased patent holdings, reaffirming its 2025 revenue guidance and projecting a 50% reduction in cash usage for the year.